DO WHAT YOU SAY !!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SSSSHHH !! I KNOW CRAZY ! Hope to get more under .02 Monday like to have a mill holding long here.....gl
QBIO !! Q BioMed announces publication of pre-clinical research showing superior safety and efficacy against current first line therapy of its drug candidate Uttroside-B for liver cancer
PR Newswire
NEW YORK, July 26, 2022
Publication in Pharmaceuticals in May 2022 is titled Augmented Efficacy of Uttroside-B over Sorafenib in a Murine Model of Human Hepatocellular Carcinoma
NEW YORK, July 26, 2022 /PRNewswire/ -- Q BioMed, Inc. (OTCQB: QBIO) a commercial-stage biotechnology development company announces a new publication supporting the potential superior safety and efficacy of its Uttroside-B chemotherapeutic to treat liver cancer vs the current first line FDA approved drug.
Liver cancer incidence rates have more than tripled since 1980, while the death rates have more than doubled during this time. More than 800,000 people are diagnosed with this cancer each year throughout the world and it accounts for more than 700,000 deaths annually. Hepatocellular Carcinoma (HCC) constitutes 90% of all liver cancer incidences, worldwide.
According to Research and Markets, the Global Sorafenib Market was valued at USD 1.08 Billion in 2020 and is projected to reach USD 1.18 Billion by 2027, growing at a CAGR of 1.21% from 2020 to 2027.
We previously reported the remarkable potency of Uttroside-B (Utt-B), against liver cancer cells. Recently, the U.S. FDA approved Utt-B as an 'orphan drug' against HCC. The current study validates the superior efficacy of Utt-B over sorafenib, the first-line FDA approved treatment option against HCC liver cancer.
The therapeutic efficacies of Utt-B vs. sorafenib against HCC were compared in vitro, using various liver cancer cell lines and in vivo, utilizing mice bearing human xenografts. The data indicate that Utt-B shows superior anti-HCC efficacy over sorafenib. Our previous report demonstrated the pharmacological safety of Utt-B in Chang Liver, the normal immortalized hepatocytes, and in the acute and chronic toxicity murine models even at high concentrations. Here, data shows that higher concentrations of sorafenib cause severe toxicity in acute and chronic in vivo models, indicating that, apart from the superior therapeutic benefit over sorafenib, Utt-B is pharmacologically safer and the drug-induced undesirable effects can be substantially alleviated in the context of HCC chemotherapy. This study highlights the therapeutic supremacy of Utt-B over sorafenib, the widely administered FDA-approved anti-HCC drug.
Denis Corin, Q BioMed CEO said, "This is another very compelling result and adds weight to the promise of an effective therapeutic for a patient population that desperately needs better and more treatment options. Having successfully completed a very challenging synthesis program, we are now finalizing manufacturing for tox studies, IND and a clinical partnership."
In more detail, researchers demonstrated the superior anti-clonogenic potential and anti-proliferating efficacy of Utt-B against liver cancer cells, compared to sorafenib in vitro. The pro-apoptotic potential of Utt-B is evident from the enhanced cleavage of caspases and significant increase in the percentage of apoptotic cells in Utt-B-treated HCC cells in comparison with sorafenib. Xenograft studies in immunocompromised murine models of human HCC exhibited a significant reduction in tumor development, with negligible side effects, in Utt-B-treated animals, whereas sorafenib treated mice exhibited symptoms of severe toxicity.
Undesirable effects associated with sorafenib chemotherapy is an impending problem in HCC patients. The present study attests to our previous report that Utt-B is pharmacologically safe up to five times the IC50 dose in acute and sub-chronic toxicity models, while even the IC50 dose of sorafenib is toxic to immunocompromised mice, and elevated doses of sorafenib induce adverse effects such as breathing problems, signs of hypertrophy, and mild regenerative changes in liver hepatocytes, in normal immune competent mice.
The researchers highlight Utt-B as a promising anti-HCC drug, owing to its enhanced therapeutic efficacy and pharmacological safety over sorafenib, the first-line treatment option for HCC.
This innovation has been granted a patent from the US, Canada, Japan and South Korea and has been conferred 'Orphan Drug' status against HCC by the U.S. FDA.
The research has been led by Dr. Ruby John Anto, a senior investigator at Rajiv Gandhi Centre for Biotechnology (RGCB). Q BioMed has the exclusive license to the technology through an agreement with RGCB and the Oklahoma Medical Research Foundation.
Please visit www.QBioMed.com for more information on our various pipeline products.
About Q BioMed Inc.
Q BioMed Inc. (Q) is a commercial-stage biomedical acceleration and development company. We are focused on licensing and acquiring biomedical assets across the healthcare spectrum. Q is dedicated to providing these target assets the strategic resources, developmental support, and expansion capital they need to ensure they meet their developmental potential, enabling them to provide products to patients in need?.
About Oklahoma Medical Research Foundation
OMRF (omrf.org) is an independent, nonprofit biomedical research institute dedicated to understanding and developing more effective treatments for human diseases. Its scientists focus on such critical research areas as cancer, diseases of aging, lupus and cardiovascular disease.
About The Rajiv Gandhi Centre for Biotechnology
RGCB is an autonomous national institution fully owned by the Government of India. It does pioneering research in cellular and molecular mechanisms of human, animal and plant disease by amalgamating theory, modeling, simulation, and experimental science.
QBIO !! HIGH-LIGHTED !
The researchers highlight Utt-B as a promising anti-HCC drug, owing to its enhanced therapeutic efficacy and pharmacological safety over sorafenib, the first-line treatment option for HCC.
This innovation has been granted a patent from the US, Canada, Japan and South Korea and has been conferred 'Orphan Drug' status against HCC by the U.S. FDA.
NEW YORK, February 10, 2023 - Q BioMed Inc. (OTCQB: QBIO) a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthcare sector, asset Uttroside B – is expected to receive a patent in the United States, adding to the already issued patents in Korea, Canada and Japan. In addition, recent results from pre-clinical pharmacokinetic testing have been very encouraging and the data supports advancing the program. Uttroside B shows tremendous value in the Liver Cancer Market. Uttroside B has also received Orphan Drug designation from the FDA.
The America Cancer Society (www.cancer.org) reported in this year alone, an estimated 42,000 adults in the United States will be diagnosed with primary liver cancer. It is also estimated that 30,000 deaths from this disease will occur this year. The 5-year survival rate is 20%, compared to just 3% 40 years ago. For the 44% of people who are diagnosed with liver cancer at an early stage, the 5-year survival rate is 34%. There is significant demand for better therapeutic alternatives in the space.
Q BioMed announced in 2021 that it has received Orphan Drug Status from the FDA. Q BioMed Inc. is prosecuting patents in multiple jurisdictions and has received patents from Canada, Korea and Japan and has now received notice of an allowable patent in the USA. The Patent is titled "Uttroside-B and Derivatives Thereof as Therapeutics for Hepatocellular Carcinoma (HCC)". Q BioMed has the exclusive rights to the technology through an agreement with the Rajiv Gandhi Centre for Biotechnology, an Autonomous Institute under the Department of Biotechnology, Government of India, and the Oklahoma Medical Research Foundation.
The global liver cancer drug market size was valued at US$824 Million in 2020 and is anticipated to grow at a CAGR of 29.4% during forecast period 2021 to 2030. In early pre-clinical investigation Q BioMed’s Uttroside-B showed ten times the cytotoxicity against HCC, which is the toxicity caused due to the action of the chemotherapeutic agent on living cancer cells, as compared to the current standard of care drug at the time. Currently, there are only two approved first-line mono therapies and a combination first-line therapy for HCC. Challenges with current treatments include patients becoming resistant to the specific drugs, adverse side effects, and high costs.
About Q BioMed Inc.
Q BioMed Inc. is a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. Q BioMed provides these target assets the strategic resources, developmental support, and expansion capital needed to ensure they meet their developmental potential, enabling them to provide products to patients in need. Please visit http://www.QBioMed.com and sign up for regular updates.
Q BioMed Media Contact:
Denis Corin CEO
https://www.qbiomed.com/news-and-media/news-2023/237-q-biomed-inc-chemotherapeutic-uttroside-b-receives-notice-of-allowance-for-patent-from-united-states-patent-office
Bullish
NEW YORK, February 10, 2023 - Q BioMed Inc. (OTCQB: QBIO) a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthcare sector, asset Uttroside B – is expected to receive a patent in the United States, adding to the already issued patents in Korea, Canada and Japan. In addition, recent results from pre-clinical pharmacokinetic testing have been very encouraging and the data supports advancing the program. Uttroside B shows tremendous value in the Liver Cancer Market. Uttroside B has also received Orphan Drug designation from the FDA.
The America Cancer Society (www.cancer.org) reported in this year alone, an estimated 42,000 adults in the United States will be diagnosed with primary liver cancer. It is also estimated that 30,000 deaths from this disease will occur this year. The 5-year survival rate is 20%, compared to just 3% 40 years ago. For the 44% of people who are diagnosed with liver cancer at an early stage, the 5-year survival rate is 34%. There is significant demand for better therapeutic alternatives in the space.
Q BioMed announced in 2021 that it has received Orphan Drug Status from the FDA. Q BioMed Inc. is prosecuting patents in multiple jurisdictions and has received patents from Canada, Korea and Japan and has now received notice of an allowable patent in the USA. The Patent is titled "Uttroside-B and Derivatives Thereof as Therapeutics for Hepatocellular Carcinoma (HCC)". Q BioMed has the exclusive rights to the technology through an agreement with the Rajiv Gandhi Centre for Biotechnology, an Autonomous Institute under the Department of Biotechnology, Government of India, and the Oklahoma Medical Research Foundation.
The global liver cancer drug market size was valued at US$824 Million in 2020 and is anticipated to grow at a CAGR of 29.4% during forecast period 2021 to 2030. In early pre-clinical investigation Q BioMed’s Uttroside-B showed ten times the cytotoxicity against HCC, which is the toxicity caused due to the action of the chemotherapeutic agent on living cancer cells, as compared to the current standard of care drug at the time. Currently, there are only two approved first-line mono therapies and a combination first-line therapy for HCC. Challenges with current treatments include patients becoming resistant to the specific drugs, adverse side effects, and high costs.
About Q BioMed Inc.
Q BioMed Inc. is a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. Q BioMed provides these target assets the strategic resources, developmental support, and expansion capital needed to ensure they meet their developmental potential, enabling them to provide products to patients in need. Please visit http://www.QBioMed.com and sign up for regular updates.
Q BioMed Media Contact:
Denis Corin CEO
https://www.qbiomed.com/news-and-media/news-2023/237-q-biomed-inc-chemotherapeutic-uttroside-b-receives-notice-of-allowance-for-patent-from-united-states-patent-office
GDVM ! ON THE MOVE ! Just busted its handle.....gl
QBIO ! 200 SMA IS AT .04 LETS WATCH !!
QBIO !! BOOM .015! Hang-on-to-your-hats-folks !!
QBIO !! VOLUME COMING BACK NOW !! Bust that .0145 an we are off again !!
QBIO ! LOW FLOAT LOVE-IT !!
Market Cap Market Cap
597,136
02/09/2023
Authorized Shares
1,000,000,000
02/06/2023
Outstanding Shares
119,427,250
02/06/2023
Restricted
9,979,696
02/06/2023
Unrestricted
109,447,554
02/06/2023
Held at DTC
109,241,125
02/06/2023
Float
41,000,000
06/26/2022
QBIO ! LOW FLOAT LOVE-IT !!
Market Cap Market Cap
597,136
02/09/2023
Authorized Shares
1,000,000,000
02/06/2023
Outstanding Shares
119,427,250
02/06/2023
Restricted
9,979,696
02/06/2023
Unrestricted
109,447,554
02/06/2023
Held at DTC
109,241,125
02/06/2023
Float
41,000,000
06/26/2022
QBIO ! BOOM THANKS FOR HEADS-UP !!
QBIO ! SEE-YEA- AT-SILVER !!
QBIO ! ABOUT TO BLOW-UP !! PENNY BREAK HERE !!
QBIO ! HUGE VOLUME !
YOU REALLY THINK ! There worth 30 mill really me not really i will get more GDV ! TANKS
clean seas ??
cant find ?
Does talk about the Walton end of year unreal taking incoming calls ?? I hate that ??
SO Frank says there is 355 mill in float unreal why dont we know that ??
GUESS THE FLOAT ! Is bigger than last update ??
LM AO !! CLNV
Clean Vision Corporation
Common Stock
0.0659
0.002
3.13%
0.063 / 0.0659 (60000 x 22478)
Real-Time Best Bid & Ask: 04:30pm 02/09/2023
Delayed (15 Min) Trade Data: 03:59pm 02/09/2023
Overview
Quote
Company Profile
Security Details
News
Financials
Disclosure
Research
CLNV SECURITY DETAILS
Share Structure
Market Cap Market Cap
26,499,092
02/08/2023
Authorized Shares
2,000,000,000
02/01/2023
Outstanding Shares
414,696,273
02/01/2023
Restricted
104,019,000
02/01/2023
Unrestricted
310,677,273
02/01/2023
Held at DTC
302,568,558
02/01/2023
Float
302,271,373
09/26/2022
EMGE ! SON OF QVC !! Going to be one.
O-YEA VEEMOST -GDVM-READ-UP !! An CLNV read-up big meeting today !!
GDVM ! GOT MORE AT .0915 ! AN THE DAMN BID IS LOWER ! WTF !
Open: Part. Filled Buy
3341
GDVM
Limit
0.0915
--
02
08
23
--
GDVM !! THANKS ! GOT SOME ! Myself >>
Filled Buy 17000 GDVM Limit 0.0915 -- -- 13:18:17 02/08/23
Filled Buy 10000 GDVM Limit 0.0915 -- -- 15:07:17 02/08/23
Filled Buy 159 GDVM Limit 0.0915 -- -- 15:07:11 02/08/23
Filled Buy 12500 GDVM Limit 0.0915 -- -- 15:07:26 02/08/23
GDVM ! NEED HELP ! That .094 is starting to be a problem.....news something ..... thanks !
GDVM ! WOW VOLUME SURGE !! NEWS ! LEAK ??
GDVM ! THANKS FOR THE CHARTS TOTHE ! I really enjoy them. The weekly bb if they start to open an i think they will we could see a dollar in a few weeks. thanks again.
CLNV ! MAYBE TODAY ?? MONDAY ?? We could use some help.
GDVM ! BRING-ON-THE-VOLUME ! Looking good Monday news ??
https://www.barchart.com/stocks/quotes/GDVM/technical-chart?plot=CANDLE&volume=total&data=I:5&density=H&pricesOn=1&asPctChange=0&logscale=0&im=5&indicators=BBANDS(20,2);SMA(20);SMA(50);SMA(100);SMA(200);ACCUM;AROONOSC(25);ATR(14);CHKMF(20);STOFA(14,3);MFI(14,100);MACD(12,26,9);RSI(14,100);TRIX(3.3);ADXMOD(14);AROON(25)&sym=GDVM&grid=1&height=500&studyheight=100
CLNV ! O-YEA NICE CLOSE ! Above the 50 sma are trend line. Tomorrow will be telling.
https://www.barchart.com/stocks/quotes/CLNV/technical-chart?plot=CANDLE&volume=total&data=DO&density=M&pricesOn=1&asPctChange=0&logscale=0&indicators=BBANDS(20,2);SMA(20);SMA(50);SMA(100);SMA(200);ACCUM;AROONOSC(25);ATR(14);CHKMF(20);STOFA(14,3);MFI(14,100);MACD(12,26,9);RSI(14,100);TRIX(3.3);ADXMOD(14);AROON(25)&sym=CLNV&grid=1&height=500&studyheight=100
CLNV !! HAMMER TIME ! HANG-ON-TO-YOUR-HATS-FOLKS !!
GDVM ! NEEDS VOLUME ! The 5 min chart is showing bb opening here with MACD crossing. Hang- on - to-your- hats - folks . We have Friday an Monday in front of us the time is near.....5 min >>
https://www.barchart.com/stocks/quotes/GDVM/technical-chart?plot=CANDLE&volume=total&data=I:5&density=H&pricesOn=1&asPctChange=0&logscale=0&im=5&indicators=BBANDS(20,2);SMA(20);SMA(50);SMA(100);SMA(200);ACCUM;AROONOSC(25);ATR(14);CHKMF(20);STOFA(14,3);MFI(14,100);MACD(12,26,9);RSI(14,100);TRIX(3.3);ADXMOD(14);AROON(25)&sym=GDVM&grid=1&height=500&studyheight=100
GDVM !! YEPPERS ! I got one of the best buys today. I just keep buying.
Filled Buy 3330 GDVM Limit 0.085 -- -- 11:29:10 02/01/23
Filled Buy 18670 GDVM Limit 0.085 -- -- 11:29:10 02/01/23
GDVM !! MONDAY NEWS !! Feels like it ......hang-on-to-your-hats-folks !!.... you have not seen nothing yet.....gl
GDVM !! YOUR A GREAT ASSET HERE ! You just dont post enough !!
VEEMOST,CISCO,INTEL !! Not worried at all just buying all i can here....gl
VEEMOST,CISCO,INTEL !! Not worried at all....gl
GDVM !! THERE IS A REASON !! These are posted on VEEMOST twitter account.
https://blogs.cisco.com/ciscoit/learning-to-swim-faster-more-easily-and-more-often
https://blogs.cisco.com/datacenter/cisco-unveils-its-most-powerful-and-energy-efficient-computing-systems
GDVM ! MOMO JUST GETTING STARTED ! To bad we have a weekend in the way. BB just starting to open on the daily. MACD cross RSI (14) only at 60 lots a room.